Demonstrated Safety Profile in DME

The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1

VISTA and VIVID: Most common adverse reactions (≥1%)1

1 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in years 1 and 2, Chart
2 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in years 1 and 2, Chart
3 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in years 1 and 2, Chart
3 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in years 1 and 2, Chart

Most common adverse reactions in patients with DME receiving EYLEA® in years 1 and 2, Chart

Less common adverse reactions reported in <1% of the patients treated with EYLEA were
hypersensitivity, retinal detachment, retinal tear, corneal edema, and injection site hemorrhage.1

VISTA and VIVID long-term safety: Most common adverse reactions2

Most common adverse reactions in patients with DME receiving EYLEA® in year 3, Chart
1 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in year 3, Chart
2 / 3
Most common adverse reactions in patients with DME receiving EYLEA® in year 3, Chart

DR phase 3 PANORAMA safety

  • Safety data observed in 269 patients with NPDR through Year 1 (Week 52) in the PANORAMA trial were consistent with those seen in the
    phase 3 VIVID and VISTA trials1
  • No new safety signals were identified through Year 2 in the PANORAMA trial compared with the known safety profile of EYLEA in the
    DR population3

NPDR, nonproliferative diabetic retinopathy; SAE, serious adverse event.

Find out more about all
EYLEA indications

Learn more about Eylea® (aflibercept) Injection, Button Learn more about Eylea® (aflibercept) Injection, Button
Enrollment form for reimbursement process, Icon
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details, Button
Product support syringe, Icon
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works, Button
Downloadable resource for HCPs, Icon
Resources

Get the information you
and your patients need
about EYLEA.

See resources, Button
References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021
  2. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology.
    2016;123(11):2376-2385. doi:10.1016/
    j.ophtha.2016.07.032
  3. Wykoff CC. Intravitreal aflibercept for moderately severe to severe non-proliferative diabetic retinopathy (NPDR): 2-year outcomes of the phase 3 PANORAMA study. Data presented at: Angiogenesis, Exudation, and Degeneration Annual Meeting; February 8, 2020; Miami, FL.